Aida Pharmaceuticals, Inc. has announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells.
It has shown positive results in the lab. Aida's researchers believe that the integration of Vasostatin-Apo2L will have higher efficacy in certain cancer treatments than currently prescribed methods.
Aida estimates that Vasostatin will have a target market of 80,000-100,000 patients per year after it is successfully brought to market and this will contribute significantly to Aida's revenue.
Vasostatin-Apo2L is developed by the same research team that created Rh-Apo2L. Rh-Apo2L has successfully completed its Phase 2 clinical testing and is going to file application with the PRC government's State Food and Drug Administration to start the Phase III trials. The development of Vasostatin-Apo2L will benefit strongly from the experience garnered in the research, manufacturing and distribution of Rh-Apo2L.